Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): Randomised controlled trial by Holt, RIG et al.
Holt, RIG and Gossage-Worrall, R and Hind, D and Bradburn, MJ and Mc-
Crone, P and Morris, T and Edwardson, C and Barnard, K and Carey, ME and
Davies, MJ and Dickens, CM and Doherty, Y and Etherington, A and French,
P and Gaughran, F and Greenwood, KE and Kalidindi, S and Khunti, K and
Laugharne, R and Pendlebury, J and Rathod, S and Saxon, D and Shiers,
D and Siddiqi, N and Swaby, EA and Waller, G and Wright, S (2019)Struc-
tured lifestyle education for people with schizophrenia, schizoaffective disor-
der and first-episode psychosis (STEPWISE): Randomised controlled trial.
British Journal of Psychiatry, 214 (2). pp. 63-73. ISSN 0007-1250
Downloaded from: http://e-space.mmu.ac.uk/623026/
Version: Published Version
Publisher: Cambridge University Press
DOI: https://doi.org/10.1192/bjp.2018.167
Usage rights: Creative Commons: Attribution 4.0
Please cite the published version
https://e-space.mmu.ac.uk
Structured lifestyle education for people with
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Tiyi Morris, Charlotte Edwardson, Katharine Barnard, Marian E. Carey, Melanie J. Davies, Chris M. Dickens,
Yvonne Doherty, Angela Etherington, Paul French, Fiona Gaughran, Kathryn E. Greenwood,
Sridevi Kalidindi, Kamlesh Khunti, Richard Laugharne, John Pendlebury, Shanaya Rathod, David Saxon,
David Shiers, Najma Siddiqi, Elizabeth A. Swaby, Glenn Waller and Stephen Wright on behalf of the
STEPWISE Research Group*
Background
Obesity is a major challenge for people with schizophrenia.
Aims
We assessed whether STEPWISE, a theory-based, group struc-
tured lifestyle education programme could support weight
reduction in people with schizophrenia.
Method
In this randomised controlled trial (study registration:
ISRCTN19447796), we recruited adults with schizophrenia,
schizoaffective disorder or first-episode psychosis from ten
mental health organisations in England. Participants were ran-
domly allocated to the STEPWISE intervention or treatment as
usual. The 12-month intervention comprised four 2.5 h weekly
group sessions, followed by 2-weekly maintenance contact and
group sessions at 4, 7 and 10 months. The primary outcome was
weight change after 12 months. Key secondary outcomes
includeddiet, physical activity, biomedicalmeasures andpatient-
related outcome measures. Cost-effectiveness was assessed
and a mixed-methods process evaluation was included.
Results
Between 10 March 2015 and 31 March 2016, we recruited 414
people (intervention 208, usual care 206) with 341 (84.4%) parti-
cipants completing the trial. At 12 months, weight reduction did
not differ between groups (mean difference 0.0 kg, 95% CI −1.6
to 1.7, P = 0.963); physical activity, dietary intake and biochemical
measures were unchanged. STEPWISE was well-received by
participants and facilitators. The healthcare perspective incre-
mental cost-effectiveness ratio was £246 921 per quality-
adjusted life-year gained.
Conclusions
Participants were successfully recruited and retained, indicating
a strong interest in weight interventions; however, the STEPWISE
intervention was neither clinically nor cost-effective. Further
research is needed to determine how tomanage overweight and
obesity in people with schizophrenia.
Declaration of interest
R.I.G.H. received fees for lecturing, consultancy work and
attendance at conferences from the following: Boehringer
Ingelheim, Eli Lilly, Janssen, Lundbeck, Novo Nordisk, Novartis,
Otsuka, Sanofi, Sunovion, Takeda, MSD. M.J.D. reports personal
fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp &
Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Servier,
Mitsubishi Tanabe Pharma Corporation, Takeda
Pharmaceuticals International Inc.; and, grants from Novo
Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, Janssen. K.K.
has received fees for consultancy and speaker for Novartis, Novo
Nordisk, Sanofi-Aventis, Lilly, Servier and Merck Sharp & Dohme.
He has received grants in support of investigator and investiga-
tor-initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis,
Lilly, Pfizer, Boehringer Ingelheim and Merck Sharp & Dohme.
K.K. has received funds for research, honoraria for speaking at
meetings and has served on advisory boards for Lilly, Sanofi-
Aventis, Merck Sharp & Dohme and Novo Nordisk. D.Sh. is expert
advisor to the NICE Centre for guidelines; board member of the
National Collaborating Centre for Mental Health (NCCMH); clin-
ical advisor (paid consultancy basis) to National Clinical Audit of
Psychosis (NCAP); views are personal and not those of NICE,
NCCMH or NCAP. J.P. received personal fees for involvement in
the study from a National Institute for Health Research (NIHR)
grant. M.E.C. and Y.D. report grants from NIHR Health
Technology Assessment, during the conduct of the study; and
The Leicester Diabetes Centre, an organisation (employer) jointly
hosted by an NHS Hospital Trust and the University of Leicester
and who is holder (through the University of Leicester) of the
copyright of the STEPWISE programme and of the DESMOND
suite of programmes, training and intervention fidelity frame-
work that were used in this study. S.R. has received honorarium
from Lundbeck for lecturing. F.G. reports personal fees from
Otsuka and Lundbeck, personal fees and non-financial support
from Sunovion, outside the submitted work; and has a family
memberwith professional links to Lilly and GSK, including shares.
F.G. is in part funded by the National Institute for Health Research
Collaboration for Leadership in Applied Health Research & Care
Funding scheme, by the Maudsley Charity and by the Stanley
Medical Research Institute and is supported by the by the
Biomedical Research Centre at South London andMaudsley NHS
Foundation Trust and King’s College London.
Keywords
Schizophrenia; psychosis; antipsychotic; obesity; overweight;
exercise; healthy diet; lifestyle; cost benefit analysis.
Copyright and usage
©The Royal College of Psychiatrists 2018. This is an OpenAccess
article, distributed under the terms of the Creative Commons
Attribution licence (http://creativecommons.org/licenses/by/
4.0/), which permits unrestricted reuse, distribution, and repro-
duction in any medium, provided the original work is properly
cited.
* See Appendix for details of the members of the STEPWISE Research
Group.
The British Journal of Psychiatry (2019)
214, 63–73. doi: 10.1192/bjp.2018.167
63
People with schizophrenia die 10–20 years earlier than the general
population, with approximately 75% of deaths resulting from phys-
ical illness.1 The twofold increased prevalence of overweight and
obesity contributes to this excess mortality.2 Some, but not all,
studies suggest that dietary and physical activity interventions
may reduce weight gain.3–7
Many weight loss programmes involve one-to-one strategies to
promote behaviour change but these are unlikely to be affordable in
many healthcare settings.8 Group-based structured education offers
an alternative approach,9 and has been adopted by the UK National
Health Service (NHS) Diabetes Prevention Programme.10 The
National Institute for Health and Care Excellence (NICE) recom-
mends that lifestyle interventions should be offered to people
taking antipsychotics but there is insufficient evidence to inform
how these should be commissioned.11
We designed the STEPWISE group-based lifestyle structured
education and then conducted a randomised controlled trial
(RCT) to evaluate whether STEPWISE could lead to clinically rele-
vant weight loss after a year in adults with schizophrenia, schizo-
affective disorder or first-episode psychosis. Further objectives
were to assess the impact on physical activity, diet, biomedical mea-
sures and quality of life, intervention fidelity, acceptability to parti-
cipants and mental health services, and cost-effectiveness.
Method
Study design
STEPWISE was a two-arm, parallel group RCT comparing the
STEPWISE intervention with treatment as usual (TAU) (study
registration: ISRCTN19447796). The study took place in ten
English NHS mental health trusts in urban and rural locations.
The trial was approved by UK National Research Ethics
Committee, Yorkshire & the Humber - South Yorkshire, (reference
14/YH/0019) and conducted in accordance with Good Clinical
Practice. The trial protocol has been reported.12
Participants
Researchers at each site worked with localmental health clinicians to
identify potentially eligible patients from clinic lists and case notes.
We used posters and leaflets to encourage self-referral. We recruited
adults (≥18 years) with a clinical diagnosis of schizophrenia, schizo-
affective disorder (ICD-10 codes F20, F25) or first-episode psychosis
(defined as <3 years since presentation to mental health services).13
The Operational Criteria Checklist (OPCRIT+) was completed
using case-note review to assess whether the clinical diagnosis
matched an objective measure of psychiatric illness.14
All participants had been prescribed an antipsychotic for ≥1
month and were able and willing to participate in a group education
programme. Participants had a body mass index (BMI) ≥25 kg/m2
(≥23 kg/m2 for South Asian and Chinese backgrounds) or
expressed concern about their weight.
People were excluded if they had a physical illness that could ser-
iously reduce their life expectancy or ability to participate, thatwould
independently have an impact on metabolic measures and weight,
for example Cushing syndrome, or were currently pregnant or less
than 6 months postpartum. High levels of psychiatric symptoms,
as judged by the principal investigator, which could seriously affect
participation and ability to put into practice the learning from the
intervention sessions were a further exclusion criterion. People
with significant alcohol or substance misuse, a primary diagnosis
of psychotic depression, mania or intellectual disability (also
known as learning disability in UK health services) were excluded.
People currently (or within the past 3 months) engaged in a
weight-management programme or unable to speak and read
English were also excluded. Participants provided written informed
consent before trial entry.
Randomisation and masking
The Sheffield Clinical Trials ResearchUnit generated a computerised
randomisation list using permuted blocks of random sizes to allocate
participants to either TAU plus the STEPWISE intervention or TAU
alone in a 1:1 ratio, stratified by site and time since antipsychotic ini-
tiation (<3months or≥3months). After randomisation, an unmasked
researcher informed the participant and their general practitioner of
the allocation. Research outcome assessors were masked to treatment
allocation. Breaks or suspected breaks in masking were recorded. The
nature of the intervention meant that participants were not masked.
Interventions
STEPWISE structured education lifestyle programme
We developed the STEPWISE intervention using the Medical
Research Council framework for complex interventions
(Supplementary Appendix 1 available at https://doi.org/10.1192/bjp.
2018.167). Following a systematic literature review, a team with
expertise in obesity, lifestyle interventions, behaviour change and
mental health and people with schizophrenia designed the prototype
intervention, which was piloted and amended in four iterative cycles.
We considered three areas that are core to weight-management
interventions in people with schizophrenia when developing the
theoretical framework that guided the intervention (Fig. 1(a)):
(a) behaviour change theory specifically with a focus on food and
physical activity;
(b) psychological processes underlying weight management;
(c) challenges of living with psychosis and its impact on eating and
weight.
Based on established psychological theories, appropriate behaviour
change techniques were used to address problem behaviours.
STEPWISE took place over approximately 12months. Groups of
participants (median 6, range 3–11) attended a foundation course of
four weekly 2.5-hour group sessions delivered by two trained facili-
tators (Fig. 1(b)). This was followed by 1:1 support contact, mostly by
telephone, lasting about 10 min, approximately every 2 weeks for the
remainder of the intervention period. A trained facilitator carried out
the support contact to promote behaviour change and continued
engagement. Further 2.5-hour group-based booster sessions took
place at approximately 4, 7 and 10 months after randomisation
giving a total intervention duration of ∼25.5 h.
All sessions started at lunchtime with the provision of a healthy
lunch. After an initial introduction, participants were invited to
‘share their story’. This provided the facilitators with feedback on
what changes the person had made and what remained challenging.
The facilitators used a non-judgemental style to encourage open-
ness, problem-solving and sharing successful strategies. Specific
changes and challenges were recorded so that the participants
could refer back to their individualised solutions.
The next part was entitled ‘Taking control of your weight’ to
reinforce the focus of the intervention. Each session covered one
or two aspects of how lifestyle changes could help the participants
take control of their weight. Four topics covered diet whereas two
focused on physical activity. A facilitative approach, as opposed to
a didactic teaching style, was used to enable participants to
discuss their beliefs about weight and explore their own solutions.
The final section was devoted to action planning, when the par-
ticipants developed their own individualised goals and solutions. As
the participants departed, they were given supporting tools to
reinforce the key messages of the session.
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Fig. 1. The STEPWISE intervention.
(a) Theoretical framework. The STEPWISE intervention was codesigned by a team with expertise in the development of obesity and lifestyle
intervention programmes, mental healthcare professionals and researchers, and service users and refined during a four-cycle pilot. It was
underpinned by self-regulation and self-efficacy theories and the relapse prevention model. (b). Curriculum. The STEPWISE intervention
comprised four 2.5 h foundation group education sessions, designed to be delivered to small groups of 6–8 participants over 4 consecutive
weeks followed by three 2.5 h follow-up ‘booster’ sessions at 3-monthly intervals and fortnightly support, usually by telephone. The content was
determined by the specific difficulties described by people with schizophrenia. The sessions incorporated adequate breaks. The educational
style was non-judgemental and facilitative to allow the participants to discuss their beliefs about weight and explore own solutions. Strategies
was employed to maintain engagement including telephone call reminders, provision of taxis to the venue, afternoon sessions with lunch
provided and use of incentives described as supporting tools. PA, physical activity; QoL, quality of life.
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Each centre had four to six trained facilitators to maintain con-
sistency across sessions and support contact. We recorded interven-
tion attendance and level of support contact. We invited
participants to complete an anonymous six-question ‘session feed-
back’ form at the end of each session (supplementary Appendix 2a).
Control arm
As no consistent lifestyle education programme was offered across
sites,15 we provided printed advice on lifestyle and the risks asso-
ciated with weight gain for all participants. We recorded whether
participants attended other weight-management or physical activity
programmes outside the trial.
Outcomes
Trial assessments were undertaken at the participant’s home or
mental health organisation, after consent but before randomisation
and at 3 and 12 months post-randomisation (supplementary
Appendix 3).
The primary end-point was weight change at 12 months after
randomisation. A medical and psychiatric history, including
smoking and current medication, was obtained. Height (baseline
only), weight, waist circumference and blood pressure were mea-
sured (supplementary Appendix 2b). Participants wore a wrist
GENEActiv accelerometer for 7 days to assess physical activity
(mean acceleration and mean time spent in moderate-to-vigorous
physical activity) (supplementary Appendix 2c).
Research staff helped participants complete the self-report ques-
tionnaires by reading the questions, checking understanding and pro-
viding available answer options. We assessed dietary intake with the
AdaptedDietary Instrument forNutritionEducationquestionnaire.16
Weusedquestionnaires to assess patient-reported outcomemeasures,
including quality of life (RAND SF-36 and EQ-5D-5L),17,18 health
beliefs (adapted Brief Illness PerceptionQuestionnaire),19 psychiatric
symptoms (Brief Psychiatric Rating Scale)20 and depressive symp-
toms (9-item Patient Health Questionnaire).21
Assessments of fasting glucose, glycated haemoglobin (HbA1c)
and lipid profile were made at baseline and 12 months post-
randomisation.
Safety assessments
Wemonitored adverse events at 3 and 12 months. Expected serious
adverse events included psychiatric hospital admissions, self-harm,
suicide attempt and death from suicide. An independent data mon-
itoring committee and trial steering committee oversaw the conduct
and safety of the trial.
Cost-effectiveness analysis
We undertook an economic evaluation from a health and social care
and societal perspective. Health and social care costs included the
costs of medicines and NHS professionals in primary and commu-
nity care and in-patient settings, and social care costs. Societal costs
were calculated using police costs, productivity losses from lost edu-
cation and employment and informal care costs. The intervention
cost was based on staff time plus overheads and included training
and supervision. The Client Service Receipt Inventory was used to
record service use.22 Costs were calculated using appropriate unit
cost information. Cost-effectiveness was assessed by combining
cost with the primary outcome and quality-adjusted life-years
(QALY) generated from the EQ-5D-5L questionnaire. We con-
structed incremental cost-effectiveness ratios to demonstrate the
cost per extra QALY gained and uncertainty around estimates
was explored using cost-effectiveness planes and acceptability
curves.
Process evaluation
We undertook a process evaluation using a published framework
and a logic model that focused on resources, activities and process
outcomes (reach, delivery, fidelity and receipt of intervention).23
Qualitative data were collected via semi-structured telephone inter-
views with participants (n = 24), intervention facilitators (n = 20)
and intervention developers (n = 7). The interviews were recorded
and coded using NVivo (QSR International v11).
Intervention delivery fidelity was monitored by direct observa-
tion using two instruments (supplementary Appendix 2d). The
Core Facilitator Behavioural Observation Sheet assessed 35 beha-
viours in six domains. Participant–educator interaction was
assessed using the DESMOND Observation Tool.24 Every 10 s,
the coder recorded whether an educator or participant was currently
talking. Silence, laughter or multiple conversations were classed as
‘miscellaneous’. This provided an objective indication of facilitator
versus participant talk time.
Sample size
The sample size calculation was based on detecting a clinically
meaningful difference of 4.5 kg (∼5% reduction in body weight).
This amount of weight loss is associated with improved lipid
profile, glucose and blood pressure and potential reductions in car-
diovascular disease.25 Based on previous UK data, we assumed a
standard deviation (s.d.) of 10 kg. A total of 260 participants (130
per arm) were required to detect this weight difference assuming
95% power and a two-sided significance level of 5%. Based on an
average of seven participants per group, and intraclass correlation
of 5% in the intervention arm, the sample size was inflated by a
design effect of 1.3 in the intervention arm yielding revised
sample sizes of 169 and 130 in the intervention and control arms,
respectively. To maintain a 1:1 allocation, 158 participants per
arm were required. We anticipated a drop-out rate of 20% giving
198 participants per arm.
Statistical analysis
All analyses were by intention to treat. The primary objective was
assessed by fitting a marginal generalised estimating equation
model adjusted for baseline weight, site and years since anti-
psychotic initiation; the model incorporated an adjustment for
potential clustering or correlation among outcomes of people
treated together. A sensitivity analysis assessed the robustness of
the findings, in particular, to missing data mechanisms (including
missing not at random), exploring whether the intervention had
the same effect among recently diagnosed participants compared
with those with longer illness duration. Other continuous outcomes
were analysed and reported as for the primary outcome. Analyses
were conducted using the Stata 14.2 software.
Results
Between 10 March 2015 and 31 March 2016, we screened 1253
patients of whom 414 enrolled (Fig. 2). The trial closed on 31
March 2017 when the last 12-month follow-up was completed.
The commonest reasons for exclusion at screening were ineligibility
and lack of interest. Two participants withdrew consent prior to the
study commencement and were not included in any analyses.
Therefore, 412 participants (207 intervention, 205 control) were
included in the final intention-to-treat analysis. In total, 168
(81.2%) intervention and 173 (84.4%) control participants com-
pleted the study, and 25 (12.1%) intervention and 22 (10.7%)
control participants withdrew consent during the study. Eleven
Holt et al
66
Assessed for eligibility (n= 1223)
Excluded (n= 800)
•   Not meeting inclusion criteria (n= 221)
•   Not interested (n = 391)
•   Not contactable (n= 32)
•   Declined consent (n= 15)
•   Unable to give informed consent (n = 13)
•   Other reasons (n= 128)a
Enrolment
Allocated to intervention (n= 208)
•   Withdrew consent and randomised in error (n= 1)
Intention-to-treat population (n= 207)
Allocated to usual care (n= 206)
•   Withdrew all consent to use their data (n= 1)
Intention-to-treat population (n= 205)
Allocation
Follow-up
Analysis
Completed 12-month follow-up (n= 168)
Lost to follow-up (n= 11)
Withdrew (n= 25)
•   Ill-health (n= 5)
•   Too time-consuming (n= 5)
•   Did not find intervention helpful (n= 4)
•   No reason given (n = 9)
•   Other (n= 2)
Died (n= 3)
Completed 12-month follow-up (n= 173)
Lost to follow-up (n= 10)
Withdrew (n= 22)
•   Ill health (n= 3)
•   Too time consuming (n = 5)
•   Preference for intervention (n = 4)
•   No reason given (n= 7)
•   Other (n= 3)
Randomised (n= 414)
Included in primary analysis (n= 167)
Excluded from analysis (n= 1)
•   Weight not recorded (n= 1)
Included in primary analysis (n = 173)
a.Referred but not contacted before end of recruitment (n= 27), current in-patient (n= 18), work (n= 9), intervention
development participant (n = 9), discharged from community mental health team (n= 8), too busy/away a lot (n= 7), 
not able to travel/out of area (n= 5), did not attend consent/baseline visit (n= 5), mental health problem relating to weight
(n= 5), unknown (n= 4), other (specified reasons) (n= 31).
Withdrew prior to randomisation (n = 9)
•   Withdrew consent (n= 4)
•   Deterioration in mental health (n = 4)
•   Scheduled for surgery (n= 1)
Did not receive allocated intervention (n= 36)*
•   Time commitment (n= 6)
•   Ill health (n= 6)
•   Felt course unhelpful (n= 2)
•   Did not attend/not stated (n= 22)
*defined as not attending at least one foundation
course
Fig. 2 STEPWISE trial CONSORT diagram.
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(5.3%) intervention and 10 (4.9%) control participants were lost to
follow-up. Three deaths occurred in the intervention arm.
At baseline, the groups were largely balanced (Tables 1 and 2),
but the intervention group were on average 3 kg heavier at baseline,
partially explained by the higher proportion of men in the interven-
tion arm (55.6% versus 46.3%). There were seven control and three
intervention participants with a BMI <25 kg/m2. The OPCRIT+
concurred with the clinical diagnosis (supplementary Appendix
4.1). Participants reported mild-to-moderate psychiatric symptoms
and took a range of antipsychotics (Table 1). Of those who com-
pleted the trial, 24 (14.3%) intervention participants and 29
(16.7%) control participants changed antipsychotic during the trial.
Intervention uptake
Participants commenced the STEPWISE intervention a median 15
days (range 1–101 days) after randomisation. Participants attended
a mean of 2.7 foundation and 1.4 booster sessions. In total, 111
(53.6%) participants attended ≥3 foundation sessions and ≥1
booster session, of whom 47 (22.7%) attended all foundation and
booster sessions. However, 36 (17.4%) participants attended no ses-
sions. Themean group size at randomisation was 6.3 (median 6) but
the mean number attending ranged from 4.0 to 4.4 (median 4)
during the foundation course and dropped to 2.7–3.0 (median 3)
during booster sessions (supplementary Appendix 4.2).
There were 169 (81.6%) participants who had one or more
support contacts, mostly by telephone (80.7% participants, 2434 con-
tacts), mail/postcard (49.3%, 555 contacts) or both (48.3%). Fewer
participants were contacted electronically (11.6%, 88 contacts) or
face to face (32.9%, 141 contacts). There were 25 (7.5%) participants
(17 intervention and 8 control) who reported attending weight loss
programmes outside the trial (supplementary Appendix 4.3).
Outcome measures
The primary comparison of weight change at 12 months was almost
identical between arms, with a mean reduction in weight of 0.47 kg
in the intervention group and 0.51 kg in the control group
Table 1 Baseline characteristics
Intervention (n = 207) Control (n = 205) Daily dose, mg: median (IQR)
Intervention (n = 207) Control (n = 205)
Age, mean (s.d.) 40.0 (11.3) 40.1 (11.5) – –
Gender, n (%)
Men 115 (55.6) 95 (46.3) – –
Women 92 (44.4) 110 (53.7) – –
Schizophrenia diagnosis type, n (%)
ICD-10: F20 145 (70.0) 138 (67.3) – –
ICD-10: F25 30 (14.5) 36 (17.6) – –
First-episode psychosis 32 (15.5) 31 (15.1) – –
Time since starting antipsychotic medication, n (%)
<1 year 12 (5.8) 12 (5.9) – –
1–2 years 11 (5.3) 20 (9.8) – –
2–5 years 28 (13.5) 19 (9.3) – –
5–10 years 28 (13.5) 33 (16.1) – –
10–20 years 71 (34.3) 69 (33.7) – –
20 or more years 57 (27.5) 52 (25.4) – –
Antipsychotic medication,a n (%)
Haloperidol (oral) 7 (3.4) 3 (1.5) 5 (5–10) 5 (1–9)
Amisulpride (oral) 21 (10.1) 16 (7.8) 400 (400–800) 175 (100–375)
Aripiprazole (oral) 37 (17.9) 28 (13.7) 10 (10–15) 10 (5–15)
Aripiprazole (long-acting injection) 3 (1.4) 6 (2.9) 14.3 (14.3–14.3) 14.3 (14.3–14.3)
Clozapine (oral) 89 (43.0) 81 (39.5) 300 (250–450) 350 (250–475)
Olanzapine (oral) 31 (15.0) 31 (15.1) 10 (5–15) 15 (10–20)
Quetiapine (oral) 28 (13.5) 24 (11.7) 350 (175–600) 250 (100–425)
Risperidone (oral) 6 (2.9) 16 (7.8) 4 (4–7) 4 (4–8)
Risperidone (long-acting injection) 4 (1.9) 5 (2.4) 3.1 (2.7–3.6) 2.7 (1.8–3.6)
Flupentixol (injection) 8 (3.9) 11 (5.4) 3.6 (3.2–5.0) 7.1 (2.9–14.3)
Zuclopenthixol (oral) 2 (1.0) 6 (2.9) 19 (10–28) 7 (6–20)
Zuclopenthixol (long-acting injection) 8 (3.9) 15 (7.3) 23.2 (11.9–32.1) 14.3 (12.1–35.7)
Paliperidone (long-acting injection) 7 (3.4) 8 (3.9) 5.4 (2.7–5.4) 3.6 (2.2–4.9)
Other antipsychotic 19 (9.2) 9 (4.4) – –
Ethnicity, n (%)
White European 179 (86.5) 170 (82.9) – –
Asian 9 (4.3) 7 (3.4) – –
Black 12 (5.8) 19 (9.3) – –
Mixed 4 (1.9) 7 (3.4) – –
Other 3 (1.4) 2 (1.0) – –
Smoking status, n (%)
Ex-smoker 55 (26.6) 52 (25.4) – –
Never smoked 54 (26.1) 45 (22.0) – –
Current smoker 98 (47.3) 108 (52.7) – –
Comorbid conditions, n (%)
Abnormal renal function 60 (29.0) 58 (28.3) – –
Hepatic disease 5 (2.4) 7 (3.4) – –
Diabetes 35 (16.9) 25 (12.2) – –
Hypertension 21 (10.1) 17 (8.3) – –
Cardiovascular disease 7 (3.4) 12 (5.9) – –
IQR, interquartile range.
a. Where long-acting injectable medications have been used, the total dose has been divided by the dosing interval. Participants may have been taking more than one antipsychotic.
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Table 2 Outcome measures at baseline, 3-month and 12-month follow-up visitsa
Baseline 3-month follow-up 12-month follow-up
Intervention group
(n = 207)
Control group
(n = 205)
Intervention group
(n = 178)
Control group
(n = 180)
Difference between
intervention and control groups
Intervention group
(n = 167)
Control group
(n = 173)
Difference between
intervention and control groups
Physical measures
Weight, kg: mean (s.d.) 105.2 (22.2) 102.1 (22.1) 104.7 (21.5) 103.1 (23.5) −0.55 (−1.44 to 0.35) 104.1 (21.1) 101.3 (23.7) 0.04 (−1.58 to 1.66)
% weight change, mean (s.d.) – – −0.2 (4.4) 0.4 (4.7) −0.4 (−1.3 to 0.5) −0.5 (7.9) −0.5 (8.3) 0.0 (−1.6 to 1.7)
Maintained or lost weight, n (%) – – 93 (52.2%) 80 (44.4%) 1.35 (0.88 to 2.05)b 98 (58.7) 88 (50.9) 1.35 (0.85 to 2.14)b
BMI,c kg/m2: mean (s.d.) 36.1 (7.2) 35.3 (7.2) 35.8 (7.1) 35.5 (7.4) −0.16 (−0.48 to 0.15) 35.6 (7.2) 34.8 (7.3) 0.05 (−0.51 to 0.61)
Waist circumference, cm: mean (s.d.) 117.8 (15.6) 116.1 (17.4) 116.8 (15.2) 115.4 (17.0) 0.79 (−0.64 to 2.22) 116.4 (16.1) 114.0 (17.7) 1.22 (−0.74 to 3.20)
Systolic blood pressure, mean (s.d.) 126 (16) 124 (17) 127 (16) 123 (16) 2.4 (0.2, 4.7) 125 (15) 122 (16) 1.7 (−1.1, 4.5)
Diastolic blood pressure, mean (s.d.) 82 (11) 82 (12) 82 (11) 81 (12) 0.4 (−1.5, 2.4) 82 (10) 81 (11) 1.1 (−0.7, 3.0)
Biochemical measures, mean (s.d.)
HbA1c, mmol/mol 42 (13) 40 (11) – – – 43 (15) 41 (14) 0.2 (−1.4 to 1.9)
Fasting glucose, mmol/L 5.9 (2.2) 5.8 (2.3) – – – 6.4 (3.0) 6.0 (2.8) 0.2 (−0.2 to 0.7)
Total cholesterol, mmol/L 5.0 (1.2) 5.1 (1.2) – – – 4.9 (1.2) 5.1 (1.1) −0.2 (−0.4 to 0.1)
HDL cholesterol, mmol/L 1.2 (0.5) 1.2 (0.4) – – – 1.2 (0.6) 1.2 (0.3) 0.0 (−0.1 to 0.1)
Triglycerides, mmol/L 2.5 (2.0) 2.2 (1.7) – – – 2.4 (1.4) 2.4 (2.2) −0.2 (−0.6 to 0.1)
Psychosocial measures, mean (s.d.)
RAND (general health) 45.0 (20.3) 44.8 (20.7) 48.0 (21.8) 46.8 (20.3) −0.3 (−3.4 to 2.8) 49.8 (23.1) 46.8 (21.4) 2.2 (−1.3 to 5.6)
EQ5D 0.793 (0.201) 0.783 (0.187) 0.815 (0.165) 0.785 (0.214) 0.02 (−0.02 to 0.054) 0.793 (0.237) 0.793 (0.239) −0.02 (−0.06 to 0.03)
B-IPQ 5.5 (1.5) 5.5 (1.7) 5.0 (1.7) 5.3 (1.7) −0.2 (−0.4, 0.0) 5.0 (1.9) 5.0 (1.7) −0.0 (−0.3, 0.3)
BPRS 30.9 (8.8) 31.5 (9.4) 30.3 (9.0) 30.4 (9.4) 0.2 (−1.3, 1.7) 29.1 (9.7) 28.3 (9.5) 1.0 (−0.9, 2.9)
PHQ-9 10.6 (6.3) 11.0 (6.8) 10.3 (6.3) 10.1 (7.1) 0.5 (−0.4, 1.3) 9.9 (7.0) 9.6 (6.6) 0.5 (−0.4, 1.5)
Physical activity, mean (s.d.)
MVPAd (all days) 13.3 (16.8) 11.0 (13.1) 13.3 (20.4) 8.8 (12.6) 2.0 (−0.9 to 4.9) 15.4 (21.7) 11.8 (19.3) 1.5 (−2.5 to 5.5)
MVPAd (weekends) 9.6 (16.6) 9.6 (14.8) 11.3 (24.9) 7.4 (12.4) 5.6 (2.0 to 9.3) 11.9 (22.1) 9.5 (19.2) 2.2 (−1.8 to 6.2)
MVPAd (weekdays) 14.4 (18.5) 11.6 (14.8) 13.8 (20.3) 9.5 (14.3) 0.9 (−2.0 to 3.8) 16.6 (24.5) 12.6 (20.1) 1.0 (−3.9 to 6.0)
Mean acceleration (all days) 21.3 (7.9) 20.8 (7.4) 21.7 (9.0) 19.8 (7.1) −0.4 (−1.5 to 0.8) 22.4 (8.2) 20.5 (8.5) 0.2 (−1.4 to 1.7)
Mean acceleration (weekends) 19.6 (8.0) 19.8 (8.3) 20.4 (9.6) 18.7 (6.9) 1.0 (−0.3 to 2.4) 20.9 (8.6) 19.4 (8.8) 0.3 (−1.5 to 2.1)
Mean acceleration (weekdays) 22.1 (8.3) 21.1 (7.1) 22.1 (9.2) 20.2 (7.5) −0.7 (−2.0 to 0.6) 23.0 (8.5) 20.9 (8.6) 0.0 (−1.6 to 1.6)
B-IPQ, Brief Illness Perception Questionnaire; BPRS, Brief Psychiatric Rating Scale; PHQ-9: 9-item Patient Health Questionnaire.
a. Statistical analysis is on the basis of intention to treat.
b. Odds ratios with 95% confidence intervals.
c. Ten participants had a body mass index (BMI) below 25 kg/m2 at baseline (ranging from 19.5 to 24.9 kg/m2); none of these was from a South Asian or Chinese background.
d. Moderate-to-vigour physical activity (MVPA) is assessed in bouts >10 min in duration. Baseline accelerometery data were obtained from 85% of participants of whom 76% provided valid data (≥4/7 days). Comparative data were available for 54% and 52% of participants at 3
and 12 months.
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(difference = 0.0 kg, 95% CI −1.6 to 1.7, P = 0.963) (Table 2 and
supplementary Appendix Fig. 4.1). There was no difference in per-
centage weight loss or percentage of participants maintaining or
losing weight.
Weight loss was modestly associated with age, with weight
reduction increasing by 0.8 kg per 10 additional years (95% CI 0.0
to 1.5 kg, P = 0.042). Participants with schizoaffective disorder
had greater mean weight loss (−2.7 kg) than those with first-
episode psychosis (−0.3 kg) or schizophrenia (+0.01 kg; P =
0.023). There was no association between treatment effect and
gender, baseline mental health, BMI, severity of psychiatric illness,
duration and change of antipsychotic treatment, or attendance at
an external weight loss programme. There was no association
between total contact time and weight loss.
The baseline self-reported diet indicated a high consumption of
refined sugar from sugary drinks and low fibre intake (supplemen-
tary Appendix 4.4). Although there was some evidence that alcohol
intake fell in the intervention group, no other dietary component
changed during the trial. Smoking status did not change (supple-
mentary Appendix 4.5).
Both groups had similarly low physical activity levels at baseline
(Table 2). After 3 months, weekend moderate-to-vigorous physical
activity was significantly higher in the intervention group, but this
difference had disappeared by 12 months. No other differences
were seen in physical activity. Self-reported patient quality of life,
obesity illness perception and psychiatric symptoms were also
similar between groups at both 3 and 12 months (Table 2 and sup-
plementary Appendix 4.6–4.7). The lack of objective changes in diet
and lifestyle in the intervention group contrasted with self-reported
changes during the ‘Sharing Stories’ part of the sessions.
At 3 months, outcome assessors were unmasked (or suspected
unmasked) at 44 (12%) of visits (intervention: 34 of 178, 19%;
control: 10 of 186, 5%). At 12 months, unmasking was recorded
for 35 (10%) of visits (intervention: 31 of 168, 18%; control: 4 of
174, 2%).
The 703 anonymous participant session feedback forms showed
87.2% of respondents indicated the session met their needs (supple-
mentary Appendix 4.8a). Forms were received from all ten sites with
the number ranging 26 to 116 (supplementary Appendix 4.8b).
Mean weight change did not correlate with mean centre feedback
scores, at 3 or 12 months (Spearmans rho =−0.20, P = 0.476 and
Spearmans rho = 0.042, P = 0.454, respectively).
Adverse events were similar between groups, except three
deaths occurred in the intervention group; none were considered
a result of the intervention (supplementary Appendix 4.9).
Cost-effectiveness analysis
The two groups had similar EQ-5D-5L scores (Health Economics
appendix). The intervention produced 0.0035 more QALYs. The
mean total health and social care costs were £5255 for STEPWISE
participants and £4453 for control participants. Themean total soci-
etal costs were £11 332 for STEPWISE participants and £10 305 for
control participants. The incremental cost-effectiveness ratio from
the healthcare perspective is £246 921 and £367 543 from the soci-
etal perspective.
Process evaluation
Facilitator and participant courses were popular, and materials were
adequately resourced, although doubts were expressed about finan-
cial sustainability. Professionals were generally motivated but
expressed the concern that in some trusts human resource and lead-
ership support were inadequate.
Fidelity assessment of intervention delivery showed overall
mean percentage facilitator talk time was 47.6% (s.d. = 12.3%)
(supplementary Appendix 4.10). ‘Positive’ (more facilitative) beha-
viours were observed for 54.1% (s.d. = 15.0%) of the time.
Conversely, ‘negative’ (more didactic) behaviours were observed
for 23.8% (s.d. = 15.4%) of the time. Problems with fidelity included
facilitators giving insufficient time for answering questions or com-
pleting tasks as well as providing rather than eliciting solutions
from participants. Although the session structure provided dedi-
cated space for participants to share their behavioural change suc-
cesses and challenges, the intervention incorporated no objective
assessment of whether participants had understood and were
acting on programme content. There was difficulty delivering tele-
phone support contacts, commonly because participants did not
answer.
Discussion
Main findings
The STEPWISE trial successfully recruited and retained partici-
pants; however, the intervention was neither clinically nor cost-
effective over the 12-month intervention period. Both groups lost
∼0.5 kg but weight change did not differ between groups. There
was no sustained behaviour change in diet and physical activity
needed to promote weight loss.
These results were unexpected as previous studies had indicated
that non-pharmacological interventions could support weight
reduction;3 however, most studies had fewer than 100 participants,
were of short duration, at moderate risk of bias and demonstrated
substantial heterogeneity of effect size.11 NICE concluded that life-
style interventions could reduce body weight in the short term but
effects beyond 6 months were unknown.11
Given our findings, we examined why the intervention did not
work and the implications for future research and clinical practice.
In terms of trial conduct, recruitment exceeded our target and sat-
isfactory retention and data completeness for the primary outcome
ensured the trial was adequately powered. The 1-year follow-up
allowed a long-term perspective and assessor masking reduced the
risk of bias.
STEPWISE was robustly developed in collaboration with people
with schizophrenia and met UK Department of Health guidelines
for structured education.26 The intervention was pragmatic,
theory-based, feasible and appeared acceptable to both people
with schizophrenia and mental healthcare professionals.27 Direct
observation of sessions, the gold-standard method for investigating
fidelity, demonstrated that, despite the higher than expected turn-
over of facilitators, the intervention was delivered as planned and
tailored appropriately.
Comparison with findings from other studies
Although our findings are at odds with the effects of short-term
interventions, other long-term studies have failed to demonstrate
a benefit of lifestyle intervention. A recent meta-analysis found sig-
nificant weight loss in only two of six studies with interventions
lasting longer than a year.7 The Danish CHANGE study, which ran-
domised 428 people with schizophrenia spectrum disorders and
abdominal obesity to 12 months of intensive lifestyle coaching
plus care coordination plus usual care, or care coordination and
usual care, or usual care alone, found no effect on body weight or
waist circumference with either intervention.6 Two other recent
UK lifestyle intervention trials have also not met their primary
outcome.28,29
It is instructive to compare the results of STEPWISE and
CHANGE with two large US trials where weight loss was achieved.
In the ACHIEVE study, the intervention group lost on average
Holt et al
70
of 3.2 kg over 18 months4 whereas in STRIDE, intervention partici-
pants lost 4.4 kg more than control participants from baseline to
6 months but this difference reduced to 2.6 kg at 1 year.5 Both
the ACHIEVE and STRIDE interventions were considerably more
intensive than STEPWISE. ACHIEVE combined group weight-
management sessions (weekly in the first 6 months then
monthly), monthly individual visits and thrice weekly group activity
classes, whereas the STRIDE study involved a 6-month weekly
group intervention followed by a total of six monthly maintenance
sessions.
The maximum face-to-face contact time in STEPWISE (17.5 h)
is similar to that recommended by the NHS Diabetes Prevention
Programme and it is debatable whether a more intensive interven-
tion would be feasible within many healthcare settings. Even
accounting for the lower cost of delivering STEPWISE in real-
world clinical practice, a more intensive programme would likely
be unaffordable, a concern raised by several facilitators. In
STEPWISE, despite the successful pilot study and use of motiv-
ational techniques to engage participants, intervention uptake was
challenging, as judged by the number of sessions attended, although
the level of engagement was similar to other group-based education
programmes.30,31
Intervention intensity, however, does not fully explain why
STEPWISE was unsuccessful as the unsuccessful CHANGE study
included weekly 1-hour sessions for a year. Both STEPWISE and
CHANGE recruited people with schizophrenia; by contrast, 41.9%
of ACHIEVE participants and 71% of STRIDE participants had
mental illness other than schizophrenia spectrum disorders, for
whom behaviour change may be easier to achieve. Whether
STEPWISE would have been more successful for those with other
psychotic illnesses, such as bipolar disorder, is unknown.
Strengths and limitations
By design, we included a broad representation of people with
schizophrenia and first-episode psychosis, although those with
high levels of psychiatric symptoms were excluded. The participants
had a spectrum of BMI from normal weight to morbid obesity. Most
had a long history of established psychiatric disorder and around
40% were taking the second-line antipsychotic, clozapine. It is pos-
sible that the intervention could have been more effective during
early psychosis, when weight gain is most rapid.2 Although we
planned to include individuals shortly after the diagnosis of first-
episode psychosis, few participants had received treatment for less
than 3 months, partly because of delays inherent in recruiting to a
group intervention.
To achievemeaningful weight loss, sustained behaviour change is
needed.At baseline, participants ate an unhealthy diet andwere phys-
ically inactive.Despite anopportunity tomake a change, the interven-
tion had little impact. One limitation of the intervention was the lack
of objective feedback about participants’ progress to facilitators. The
process evaluation indicated that facilitators wanted more informa-
tion about participant weight change and nutritional and exercise
plans to check understanding of session content and monitor
dietary or physical activity changes against action plans.
Notwithstanding the negative results, the trial has important
findings. Despite concerns about undertaking trials in this popula-
tion, we successfully delivered the largest trial in this area with a
12-month follow-up across a diverse group of community mental
health teams. We achieved our recruitment target 3 months ahead
of schedule and maintained participants throughout the year-long
trial. The trial also highlighted patient and healthcare professional
demand for weight-management programmes within mental
health settings and, in response, several trusts increased their phys-
ical health monitoring and engagement with weight management.
Participants also valued sharing experiences with other people
with schizophrenia with similar weight problems.
Implications
The challenge of managing obesity and weight gain in people with
schizophrenia remains and other approaches are needed.
STEPWISE focused on lifestyle modification rather than the
breadth of contributors to weight gain and obesity. Antipsychotics
are associated with weight gain while psychosis and psychological
factors can impede weight loss behaviours. Broader approaches
that combine individually tailored lifestyle modification with psy-
chological interventions for mental health, adjustment of anti-
psychotic treatment or co-prescription with drugs, such as
metformin, may be needed.32
Although it is clear that lifestyle change is needed for people
with schizophrenia, STEPWISE has shown how difficult this is to
achieve. NICE guidance currently recommends ‘people with psych-
osis or schizophrenia, especially those taking antipsychotics, should
be offered a combined healthy eating and physical activity pro-
gramme by their mental healthcare provider’.11 Before these lifestyle
interventions are commissioned across the NHS, it is vital that
further research is undertaken to address how best to support
weight management.
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